SearcharxivSearch

arXiv subjects

Francois Mercier

Publications and source records attributed to Francois Mercier.

4 recordsLinked to original sources

Clustering-Based Outcome Models for Clinical Studies: A Scoping Review

This review provides a systematic overview of methods that combine covariate-based clustering of observational units (patients) with outcome models for clinical studies. We distinguish between informed-cluster models, where the outcome contributes to cluster formation, and agnostic-cluster models, where clustering is performed solely on covariates in a separate first step. Informed-cluster models include product partition models with covariates (PPMx), finite mixtures of regression models (FMR), and cluster-aware supervised learning (CluSL). Agnostic-cluster models encompass two-step procedures using either model-based or algorithmic clustering followed by cluster-specific regression models. Following a systematic search of Web of Science and PubMed, 55 records were identified that propose or evaluate such models. We describe the key models, summarise study characteristics, and present applications from biomedical and public health research. Clustering-based outcome models are particularly relevant for settings with high-dimensional covariates (e.g., biomarker panels and "omics") and heterogeneous patient populations. These models can support risk stratification and we discuss extensions to estimate subgroup-specific treatment effects. They are most valuable when the population is clustered in distinct regions of the covariate space that correspond to different outcome distributions. We discuss applications to rare disease research, covariate adjustment and borrowing from historical data, and subgroup-specific treatment effect estimation in clinical trials.

stat.ME

Dynamic Prediction for Hospital Readmission in Patients with Chronic Heart Failure

Hospital readmission among patients with chronic heart failure (HF) is a major clinical and economic burden. Dynamic prediction models that leverage longitudinal biomarkers may improve risk stratification over traditional static models. This study aims to develop and validate a joint model using longitudinal N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements to predict the risk of rehospitalization or death in HF patients. We analyzed real-world data from the TriNetX database, including patients with an incident HF diagnosis between 2016 and 2022. The final selected cohort included 1,804 patients. A Bayesian joint modeling framework was developed to link patient-specific NT-proBNP trajectories to the risk of a composite endpoint (HF rehospitalization or all-cause mortality) within a 180-day window following hospital discharge. The model's performance was evaluated using 5-fold cross-validation and assessed with the Integrated Brier Score and Integrated Calibration Index. The joint model demonstrated a strong predictive advantage over a benchmark static model, particularly when making updated predictions at later time points (180-360 days). A joint model trained on patients with more frequent NT-proBNP measurements achieved the highest accuracy. The main joint model showed excellent calibration, suggesting its risk estimates are reliable. Our findings suggest that modeling the full trajectory of NT-proBNP with a joint modeling framework enables more accurate and dynamic risk assessment compared to static, single-timepoint methods. This approach supports the development of adaptive clinical decision-support tools for personalized HF management.

stat.AP

Duration of and time to response in oncology clinical trials from the perspective of the estimand framework

Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the best overall response (BOR) and presented as the overall response rate (ORR). Despite common use of DOR and TTR in particular in single-arm studies, the definition of these endpoints and the questions they are intended to answer remain unclear. Motivated by the estimand framework, we present relevant scientific questions of interest for DOR and TTR and propose corresponding estimand definitions. We elaborate on how to deal with relevant intercurrent events which should follow the same considerations as implemented for the primary response estimand. A case study in mantle cell lymphoma illustrates the implementation of relevant estimands of DOR and TTR. We close the paper with practical recommendations to implement DOR and TTR in clinical study protocols.

stat.ME

Discovering material information using hierarchical Reformer model on financial regulatory filings

Most applications of machine learning for finance are related to forecasting tasks for investment decisions. Instead, we aim to promote a better understanding of financial markets with machine learning techniques. Leveraging the tremendous progress in deep learning models for natural language processing, we construct a hierarchical Reformer ([15]) model capable of processing a large document level dataset, SEDAR, from canadian financial regulatory filings. Using this model, we show that it is possible to predict trade volume changes using regulatory filings. We adapt the pretraining task of HiBERT ([36]) to obtain good sentence level representations using a large unlabelled document dataset. Finetuning the model to successfully predict trade volume changes indicates that the model captures a view from financial markets and processing regulatory filings is beneficial. Analyzing the attention patterns of our model reveals that it is able to detect some indications of material information without explicit training, which is highly relevant for investors and also for the market surveillance mandate of financial regulators.

q-fin.ST